Back to top

Image: Bigstock

Is Inogen (INGN) Stock Outpacing Its Medical Peers This Year?

Read MoreHide Full Article

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Inogen (INGN - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of INGN and the rest of the Medical group's stocks.

Inogen is a member of our Medical group, which includes 817 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. INGN is currently sporting a Zacks Rank of #1 (Strong Buy).

Over the past three months, the Zacks Consensus Estimate for INGN's full-year earnings has moved 16.93% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Based on the latest available data, INGN has gained about 64.07% so far this year. Meanwhile, stocks in the Medical group have gained about 4.96% on average. This means that Inogen is outperforming the sector as a whole this year.

Looking more specifically, INGN belongs to the Medical - Instruments industry, a group that includes 92 individual stocks and currently sits at #81 in the Zacks Industry Rank. On average, stocks in this group have gained 15.47% this year, meaning that INGN is performing better in terms of year-to-date returns.

Going forward, investors interested in Medical stocks should continue to pay close attention to INGN as it looks to continue its solid performance.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Inogen, Inc (INGN) - free report >>

Published in